首页> 外文期刊>Journal of Virological Methods >Development and validation of a real-time RT-PCR assay for the quantification of rabies virus as quality control of inactivated rabies vaccines
【24h】

Development and validation of a real-time RT-PCR assay for the quantification of rabies virus as quality control of inactivated rabies vaccines

机译:用于定量狂犬病病毒的实时RT-PCR测定作为灭活狂犬病疫苗的质量控制的实时RT-PCR测定的开发和验证

获取原文
获取原文并翻译 | 示例
           

摘要

Rabies is an infectious viral disease, characterized as a neglected zoonosis, responsible for nearly 60,000 deaths annually. The virus is transmitted mainly by dogs in Africa and Asia, and wildlife in Europe and the Americas, to all mammals' species, causing severe encephalitis almost always fatal after the onset of neurological symptoms. Human rabies can be prevented through extensive vaccination of dogs and pre/postprophylaxis treatments in humans with inactivated rabies vaccines. The vaccine manufacture involves a series of quality control assays using laboratory animals, which are mandatory to exclude the presence of viable residual virus. The quality controls must be carried out in various steps during the vaccine production, which demands the use of a large number of animals. In this study, we standardized a real-time quantitative RT-PCR duplex assay to be used during intermediate stages of the vaccine production. This assay was done for the quantification of vaccine strain rabies virus, targeting rabies nucleoprotein, and (3 actin mRNA of BHK-21 cells as an internal endogenous control. The results showed specific amplification, with the analytical sensitivity ranged from 10(1) to 10(6) TCID50/mL with high repeatability rate for the quantification of rabies virus in inactivated vaccine samples. Global organizations are engaged to develop new approaches to determine viable residual virus, and this assay can be applied in combination with traditional in vitro methods for the release of intermediate batches of vaccines during the production process, keeping the in vivo tests only for final release.
机译:狂犬病是一种传染性病毒疾病,其特征为被忽视的人群病,每年负责近60,000人死亡。病毒主要由非洲和亚洲和欧洲和美洲的野生动物传播到所有哺乳动物的物种,导致严重的脑炎几乎总是在神经症状发作后几乎致命。通过灭活狂犬病疫苗的人类的狗和前/后期治疗可以防止人类狂犬病。疫苗制造涉及使用实验室动物的一系列质量控制测定,这是强制性的,以排除存在活性残留病毒的存在。在疫苗生产过程中必须在各种步骤中进行质量控制,这需要使用大量的动物。在这项研究中,我们标准化了在疫苗生产的中间阶段使用的实时定量RT-PCR双链测定。该测定是为了定量疫苗菌株狂犬病病毒,靶向狂犬病核蛋白,以及(作为内部内源对照的3个肌动蛋白mRNA的BHK-21细胞。结果表现出特异性扩增,分析敏感度范围为10(1)到10(6)TCID50 / ml具有高可重复性率的狂犬病病毒在灭活疫苗样本中的定​​量。全球组织从事开发新方法以确定可行性残留病毒,并且该测定可以与传统的体外方法组合使用在生产过程中释放中间批量疫苗,仅保持体内测试仅用于最终释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号